HZNP · Horizon Therapeutics
Acquired Company
Amgen completed the acquisition of Horizon Therapeutics plc on 10/6/2023 for $116.50 per share in cash, representing a transaction value of approximately $27.8 billion.
Acuired by Amgen 10/3/23. Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The Company pipeline is purposeful: it applyie scientific expertise and courages to bring clinically meaningful therapies to patients. The Company believes science and compassion must work together to transform lives.
Market Cap
N/A
52 Wk Range
N/A - N/A
Previous Close
$116.30
Open
$116.30
Volume
N/A
Day Range
$116.30 - $116.30
Enterprise Value
N/A
Cash
N/A
Avg Qtr Burn
N/A
Insider Ownership
1.18%
Institutional Own.
N/A
Qtr Updated
Jun 30th 2024